We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · July 01, 2021

Clinical Effectiveness of Olaparib Monotherapy in Germline BRCA-Mutated, HER2− Metastatic Breast Cancer

European Journal of Cancer


Additional Info

Disclosure statements are available on the authors' profiles:

European Journal of Cancer
Clinical Effectiveness of Olaparib Monotherapy in Germline BRCA-Mutated, HER2-Negative Metastatic Breast Cancer in a Real-World Setting: Phase IIIb LUCY Interim Analysis
Eur. J. Cancer 2021 Jun 01;152(xx)68-77, KA Gelmon, PA Fasching, FJ Couch, J Balmaña, S Delaloge, I Labidi-Galy, J Bennett, S McCutcheon, G Walker, J O'Shaughnessy

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading